An interventional study of Vericiguat in Hemodialysis Complication and Heart Failure, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment
Chronic Kidney Disease often requires dialysis and other treatments to sustain life, and patients frequently suffer from heart failure, which exacerbates the disease burden. Research has shown that the incidence of heart failure is high among patients on dialysis, and the prognosis is poor. In recent years, there has been significant progress in the treatment of heart failure. Vericiguat, a novel sGC stimulator, can improve cardiac function and exercise tolerance, reduce the risk of cardiovascular death and hospitalization for heart failure, and has good tolerance. It has been included in relevant guidelines as a recommended drug. It has good tolerance in patients with renal insufficiency, and its therapeutic effect is consistent in patients with different levels of eGFR. However, there is a lack of prospective, randomized controlled studies targeting the special population of patients on dialysis. This study is a prospective, observational, single-arm study, planning to recruit 118 patients from June 2025 to June 2026. It aims to assess the efficacy and safety of Vericiguat in patients with heart failure on hemodialysis, to provide new evidence-based medical evidence for the treatment of heart failure in this special population, optimize the treatment strategy, and improve the prognosis and quality of life.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 118 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Guangdong Provincial People's Hospital is the lead sponsor of 231 studies on the registry; 101 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.
Drug: Vericiguat
Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.
Left ventricular ejection fraction(LVEF)
Change from baseline in left ventricular ejection fraction(LVEF)between baseline and end of study
Time frame: 12weeks
Left ventricular ejection fraction (LVEF)
Change from baseline in left ventricular ejection fraction (LVEF) between baseline and end of study
Time frame: 12weeks
N terminal proB type natriuretic peptide (NT-prpBNP)
Blood samples will be collected for analysis of concentration of N terminal pro B type natriuretic pel proBNP) every 2 weeks
Time frame: 12 weeks
Left ventricular end diastolic volume (LVEDV)
LVEDV is measured as baseline and after 12 weeks follow-up.
Time frame: 12 weeks
Left atrial volume (LAV)
LAVis measured as baseline and after 12 weeks follow-up.
Time frame: 12 weeks
The ratio of mitral early diastolic blood flow peak and mitral annulus velocity (E/E')
E/E' is measured as baseline and after 12 weeks follow-up.
Time frame: 12 weeks
Pulmonary Artery Pressure
Pulmonary Artery Pressure is measured as baseline and after 12 weeks follow-up.
Time frame: 12 weeks
Concentration of high-sensitivity serum troponin T
Blood samples will be collected for analysis of concentration of serum troponin every 4 weeks.
Time frame: 12 weeks
Minnesota Heart Failure Quality of Life Questionnaire (LiHFe)
Change in health status is assessed using the disease-specific Minnesota Heart Failure Quality of L Questionnaire.
Time frame: 12 weeks
Systolic and diastolic blood pressure
Systolic and diastolic blood pressure will be measured every 2 weeks.
Time frame: 12 weeks
Electrocardiogram(ECG)
ECG QT Interval analysis was performed at baseline and 12 weeks follow-up.
Time frame: 12 weeks
Estimated glomerular filtration rate(eGFR)
changes in estimated glomerular filtration rate(eGFR)
Time frame: 12 weeks
Neprilysin
The concentration of Neprilysis is measured by Human Neprilysin ELISA Kit as baseline and after 12 weeks following up
Time frame: 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Provincial People's Hospital